Research programme: antibacterials - Provid
Latest Information Update: 04 Apr 2008
At a glance
- Originator Provid Pharmaceuticals
- Class
- Mechanism of Action DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 15 Jan 2004 Preclinical trials in Bacterial infections in USA (unspecified route)